Clinical trials: Patient With Schizophrenia Spectrum Disorder
Schizophrenia
A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment fo Schizophrenia or Schizoaffective Disorder in Hospitalized Patients
The purpose of this study is to compare the efficacy and safety of ziprasidone and aripiprazole in hospitalized patients with schizophrenia or schizoaffective disorder
- Trial name
- NCT00634348
- Testing
- Aripiprazole, Ziprasidone
- Where
- 41 sites in United States
- Volunteers
- 256 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia
Biomarker and Safety Study of Clozapine in Patients With Benign Ethnic Neutropenia (BEN)
Clozapine (CLZ) is the most effective antipsychotic for treatment-refractory schizophrenia (SZ). Despite the overwhelming evidence of superior efficacy, CLZ is infrequently prescribed in the US, at a considerably lower rate than…
- Trial name
- BEN (NCT02404155)
- Testing
- Clozapine
- Where
- United States
- Volunteers
- 274 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia
Shared Decision Making for Patients With First-admission Schizophrenia
To determine whether shared decision making (SDM) intervention improves patient satisfaction in patients with first-admission schizophrenia compared with usual care.
- Trial name
- NCT01869660
- Testing
- Shared Decision Making
- Where
- Japan
- Volunteers
- 23 people
- Sponsor
- Yokohama City University
Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders
Berberine as Adjuvant Treatment for Schizophrenia Patients
One double-blind, randomized, placebo-controlled trial is designed to examine whether berberine added to current antipsychotic drugs could produce significantly greater efficacy in reducing atypical antipsychotic-induced…
- Conditions
- Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders, Metabolic Syndrome x
- Trial name
- BER (NCT02983188)
- Testing
- Berberine, Antipsychotic Agents
- Where
- Hong Kong
- Volunteers
- 113 people
- Sponsor
- The University of Hong Kong
Schizophrenia and Related Disorders, Psychotic Disorder
Thinking Skills at Work: Cognitive Remediation Therapy for Patients With Serious Mental Illness
The purpose of this study is to help people with serious mental illness get and keep the job they want by improving their thinking skills, using cognitive remediation therapy.
- Trial name
- TSW (NCT03483701)
- Testing
- Cognitive Remediation Therapy
- Where
- Canada
- Volunteers
- 105 people
- Sponsor
- Fraser Health
Schizophrenia
Patient-reported Outcomes in the Treatment of Schizophrenia
Patient-reported health economic outcomes for patients enrolled in S1543003 and S1543004 protocols
- Trial name
- NCT00230828
- Testing
- bifeprunox
- Sponsor
- Solvay Pharmaceuticals
Schizophrenia, Cognition Disorders
The Effect of Nicotine on Arousal, Cognition and Social Cognition in Schizophrenic Patients
This study in patients with stable schizophrenia will investigate the effect of nicotine on arousal, cognitive task and social cognition after acute dose administration.
- Trial name
- NCT01186471
- Testing
- A643 (nicotine)
- Volunteers
- 32 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Schizophrenia
iTBS for Increased Appetite Induced by Antipsychotics
Antipsychotics are prone to cause metabolic side effects, including weight gain, hyperglycemia, insulin resistance, hyperlipidemia and so on, leading to a 2-3 times higher risk of death in patients with schizophrenia compared to…
- Trial name
- NCT05783063
- Testing
- Active iTBS
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Central South University
Schizophrenia
A Study of RO4917838 in Combination With Antipsychotic Treatment in Patients With Schizophrenia.
This study will determine the efficacy and safety of RO4917838 in patients with schizophrenia who are stable on current antipsychotic treatment (olanzapine, que tiapine, risperidone, paliperidone or aripiprazole) with prominent…
- Trial name
- NCT00616798
- Testing
- RO4917838, Standard antipsychotic therapy
- Where
- 73 sites in United States, Austria and 8 more
- Volunteers
- 323 people
- Sponsor
- Hoffmann-La Roche
Schizophrenia, Metabolic Syndrome
CHANGE -it is About Life
Schizophrenia is a life shortening disease, not only because of suicide but also because of increased mortality from natural causes.
- Trial name
- NCT01585493
- Testing
- Treatment as usual, Care coordinator, CHANGE
- Where
- Denmark
- Volunteers
- 428 people
- Sponsor
- Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Schizophrenia, Schizoaffective Disorder
Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia
This is a 12-week, randomized, double-blinded, placebo-controlled trial of telmisartan 80 mg/day as an adjunctive to clozapine or olanzapine therapy, in 70 schizophrenia subjects to examine telmisartan's effect on glucose…
- Trial name
- NCT00981526
- Testing
- Telmisartan, Clozapine, Olanzapine
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- University of Massachusetts, Worcester
Schizophrenia
A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients
The primary objective of this study was to assess time to discontinuation due to lack of tolerability among patients with schizophrenia receiving LY2140023, given orally twice daily for 24 weeks, versus those on atypical…
- Trial name
- NCT00845026
- Testing
- LY2140023, aripiprazole, olanzapine
- Where
- 23 sites in United States, Germany and 2 more
- Volunteers
- 261 people
- Sponsor
- Denovo Biopharma LLC
Schizophrenia
A Study of Extended Release Extended-release (ER) OROS Paliperidone Tolerability, as Compared to Immediate-release (IR)Risperidone, in Patients With Schizophrenia
The purpose of this study is a noninferiority comparison of the orthostatic tolerability of a dose of 12 mg extended-release (ER) OROS paliperidone with the current recommended initial titration dose (2 mg) of immediate-release…
- Trial name
- NCT00791232
- Testing
- extended-release (ER) OROS paliperidone
- Volunteers
- 113 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Psychoeducation for Vietnamese Families With a Patient With Schizophrenia
Families with a patient with schizophrenia and the patient are randomly assigned to receive either a 3 session psychoeducation program, or no psychoeducation.
- Trial name
- NCT02715349
- Testing
- Psychoeducation
- Where
- Vietnam
- Volunteers
- 59 people
- Sponsor
- Danang Psychiatric Hospital
Schizophrenia
Phase IIA Study in Patients With Schizophrenia
This study is designed to assess the effects of AZD 2624 in patients with schizophrenia
- Trial name
- NCT00686998
- Testing
- AZD2624, Olanzapine
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- AstraZeneca
Schizophrenia
Antidepressant Treatment in Older Adults With Schizophrenia
The purpose of this study is to evaluate the safety and effectiveness of citalopram (Celexa) for the treatment of depressive symptoms in middle-aged and elderly patients with schizophrenia.
- Trial name
- NCT00047450
- Testing
- Citalopram (Celexa)
- Where
- 2 sites in United States
- Volunteers
- 212 people
- Sponsor
- Veterans Medical Research Foundation
Schizophrenia, Bipolar Disorder
Aripiprazole Open-Label, Safety and Tolerability Study
The purpose of this study is to test the long-term safety and tolerability of aripiprazole in adolescent patients with schizophrenia, and child and adolescent patients with bipolar I disorder, manic or mixed episode.
- Trial name
- APEX 241 (NCT00102518)
- Testing
- Aripiprazole
- Where
- 50 sites in United States
- Volunteers
- 325 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)
This is a Phase 3, multicenter, 53-week, outpatient, open-label extension (OLE) study to evaluate the long-term safety, tolerability, and efficacy of KarXT in subjects with Diagnostic and Statistical Manual-Fifth Edition (DSM-5)…
- Trial name
- NCT04659174
- Testing
- Xanomeline and Trospium Chloride Capsules
- Where
- 44 sites in United States, Ukraine
- Volunteers
- 152 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Schizophrenia
Emotion Endophenotypes in Schizophrenia
Schizophrenia is an invalidating psychiatric illness with a strong genetic component characterized by abnormal processing of emotional information.
- Trial name
- SCHIZOIMAGEN (NCT02834208)
- Testing
- MRI (Magnetic resonance imaging), Polymorphism (SNP in DNA), quantitative measures of mRNA
- Where
- France
- Volunteers
- 105 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Schizophrenia
A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia
The primary objective of the study is to evaluate the long-term safety and tolerability of TV-46000. The primary safety and tolerability endpoint is the frequency of all adverse events, including serious adverse events.
- Trial name
- SHINE (NCT03893825)
- Testing
- TV-46000
- Where
- 90 sites in United States, Bulgaria and 3 more
- Volunteers
- 336 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.